Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. News
BriaCell Therapeutics Corp. Quantitative Score
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
BriaCell Therapeutics Corp. Financials
Table Compare
Compare BCTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | BCTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BCTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BCTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BCTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
BriaCell Therapeutics Corp. Income
BriaCell Therapeutics Corp. Balance Sheet
BriaCell Therapeutics Corp. Cash Flow
BriaCell Therapeutics Corp. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
BriaCell Therapeutics Corp. Executives
| Name | Role |
|---|---|
| Dr. William V. Williams FCPA, M.D. | Chief Executive Officer, President & Director |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer & Corporate Secretary |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. William V. Williams FCPA, M.D. | Chief Executive Officer, President & Director | 1955 | 734.42K | |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer | 1962 | 540.33K | |
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer & Corporate Secretary | Male | 1973 | 443K |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer | 1970 | 357.75K | |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board | 1946 | 241.14K |
BriaCell Therapeutics Corp. Insider Trades
| Date | 14 May |
| Name | Lustig Marc |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 902935 |
| Date | 14 May |
| Name | Lustig Marc |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 902935 |
| Date | 28 Dec |
| Name | Bondarenko Jamieson |
| Role | Chairman |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 28000 |
| Date | 23 Dec |
| Name | Williams William V. |
| Role | President, CEO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2530 |
| Date | 20 Dec |
| Name | Bondarenko Jamieson |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 22000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 May | Lustig Marc | Director, 10 percent owner | Acquired | P-Purchase | 902935 |
| 14 May | Lustig Marc | Director, 10 percent owner | Acquired | P-Purchase | 902935 |
| 28 Dec | Bondarenko Jamieson | Chairman | Acquired | P-Purchase | 28000 |
| 23 Dec | Williams William V. | President, CEO | Acquired | P-Purchase | 2530 |
| 20 Dec | Bondarenko Jamieson | Director | Acquired | P-Purchase | 22000 |